Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.09
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Optiscan Imaging Limited develops and commercializes confocal microscopes for clinical and pre-clinical applications in Australia, Germany, and Internationally. It offers FIVE2 (ViewnVivo) system, a miniaturized confocal endomicroscopes use for clinical, translational, pre-clinical, and other research. The company also engages in the development of InVivage device for use in cancer screening and surgery. Optiscan Imaging Limited...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell